Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02099825 · ClinicalTrials.gov registry record · Phase 1
Medication Enhanced Rapid Therapy
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02099825 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 15 participants.
The verdict
NCT02099825, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether taking a one-time dose of a combination of putatively learning-enhancing medications can improve treatment response to a brief learning-based psychotherapy for public speaking anxiety. The two medications are (1) d-cycloserine (DCS), a medication that is an agonist (facilitator) of the NMDA glutamatergic receptor and has been shown in previous studies to facilitate some kinds of learning and memory; and (2) mifepristone, a medication that blocks cortisol, and in preclinical (animal) studies has been shown to reverse certain kinds of stress-related learning impairment or negative learning. Specifically, the investigators goal is to determine if DCS and mifepristone taken together augment the learning that occurs during a brief psychotherapy session---a public speaking exposure exercise. Evidence for this learning effect would be a finding that participants have reduced anxiety at subsequent public speaking exposures.
Interventions
- DRUG d-cycloserine and mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-01-13 |
| Est. Completion | 2022-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02099825
The ClinicalTrials.gov registry entry for NCT02099825 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which d-cycloserine and mifepristone is the first listed.
NCT02099825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02099825 about?
NCT02099825 is a clinical study titled "Medication Enhanced Rapid Therapy". The purpose of this research study is to determine whether taking a one-time dose of a combination of putatively learning-enhancing medications can improve treatment response to a brief learning-based psychotherapy for public speaking anxiety. The two medications are (1) d-cycloserine (DCS), a medic...
What is the current status of trial NCT02099825?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-01-13. Estimated completion is 2022-10.
What interventions are being tested in trial NCT02099825?
The interventions under investigation include: d-cycloserine and mifepristone (DRUG).
Who is sponsoring clinical trial NCT02099825?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.